Targeting ASCT2 provides a new option for tumour therapy, but due to the existence of tumour metabolic heterogeneity, not all patients can benefit from ASCT2 inhibition, interference with glutamine metabolism treatment strategies. This evidence concerns the gene SLC1A5 and neoplasm.